Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Leases: 2019-2024

Historic Current Leases for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $11.6 million.

  • Kymera Therapeutics' Current Leases rose 3.00% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year increase of 3.00%. This contributed to the annual value of $11.6 million for FY2024, which is 128.77% up from last year.
  • Kymera Therapeutics' Current Leases amounted to $11.6 million in FY2024, which was up 128.77% from $5.1 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' Current Leases peaked at $11.6 million during FY2024, and registered a low of $2.5 million during FY2021.
  • In the last 3 years, Kymera Therapeutics' Current Leases had a median value of $5.1 million in 2023 and averaged $6.4 million.
  • In the last 5 years, Kymera Therapeutics' Current Leases decreased by 4.60% in 2020 and then surged by 128.77% in 2024.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Current Leases stood at $2.6 million in 2020, then dropped by 4.32% to $2.5 million in 2021, then increased by 3.01% to $2.5 million in 2022, then soared by 99.92% to $5.1 million in 2023, then soared by 128.77% to $11.6 million in 2024.